New stock news | Yimei Intelligent Technology intends to list on the Hong Kong stock market. The China Securities Regulatory Commission requires additional information on the participants in the company's equity incentive plan.
On July 10th, the China Securities Regulatory Commission announced the "Supplementary Material Requirements for Overseas Issuance and Listing (July 6, 2026 - July 10, 2026)".
On July 10th, the China Securities Regulatory Commission (CSRC) announced the "Supplementary Materials Requirements for Overseas Issuance and Listing Applications (July 6, 2026 - July 10, 2026)." The CSRC's International Department issued supplementary material requirements for 7 companies. Among them, Yimi Zhike was required to provide further clarification on whether participants in the company's equity incentive plan are employees of the company and whether there are external personnel. According to the disclosure on April 1st by the Hong Kong Stock Exchange, Shenzhen Yimi Zhike Technology Co., Ltd. (referred to as Yimi Zhike) submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CICC and CMSC International as its joint sponsors.
The CSRC requested Yimi Zhike to provide explanations on the following matters, and to have lawyers verify and provide clear legal opinions:
1. Please explain the basis for the company's previous capital increases and equity transfer pricing, whether the capital has been paid in, whether there are cases of failure to fulfill capital obligations, misappropriation of capital, or flaws in the capital contribution method, and provide a clear conclusive opinion on the legality and compliance of previous equity changes.
2. Regarding this issuance and listing, and "full circulation": (1) Please explain the expected amount of funds to be raised after full exercise of the over-allotment option; (2) Please explain whether the shares held by the shareholders intending to participate in "full circulation" are subject to pledges, freezes, or other defects.
3. Please provide additional information on whether the company and its subsidiaries' business scope and actual operations involve restricted or prohibited areas for foreign investment, and whether they continue to meet the requirements for foreign investment access after this issuance and listing and "full circulation."
4. Please explain whether participants in the company's equity incentive plan are company employees, whether there are external personnel, and provide a clear conclusive opinion on the fairness of the prices of the implemented equity incentive plan and the presence of any conflict of interest.
5. Please provide updates on the progress of handling overseas reinvestment reporting procedures for the issuer's overseas subsidiaries.
The prospectus shows that Yimi Zhike is deeply involved in the global semiconductor quality control field, dedicated to providing PCB quality control solutions. PCB is a key basic carrier for signal transmission and component integration in the global semiconductor ecosystem. According to data from Zhoushi Consulting, based on revenue in 2025, the company is the largest PCB quality control solution provider in China and the second largest in the world, with market shares of 13.8% and 8.4% respectively.
The company's PCB quality control solution integrates its self-designed and developed optical and electrical performance testing equipment, proprietary software, and full lifecycle support services, aiming to help PCB manufacturers achieve higher accuracy, reliability, and efficiency in testing throughout the production process. Their customized solutions cover end-to-end testing solution design, individual equipment configuration, and testing line layout, seamlessly connecting with customer production lines.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
.png)
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

RECOMMEND





